These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 36196725

  • 21. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
    Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoruso F, Balato A, Bardazzi F, Brianti P, Brunasso G, Burlando M, Cagni AE, Caproni M, Carrera CG, Carugno A, Caudullo F, Cuccia A, Dapavo P, Di Brizzi EV, Dini V, Gaiani FM, Gisondi P, Guarneri C, Lasagni C, Licata G, Loconsole F, Marzano AV, Megna M, Mercuri SR, Musumeci ML, Orsini D, Ribero S, Ruffo Di Calabria V, Satolli F, Strippoli D, Travaglini M, Trovato E, Venturini M, Zichichi L, Valenti M, Costanzo A, Narcisi A.
    J Dermatolog Treat; 2024 Dec; 35(1):2350760. PubMed ID: 38714323
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L.
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S, Kanai Y, Murotani K, Nomura T, Ito K, Ohata C, Yamazaki F, Miyagi T, Takahashi H, Okubo Y, Saeki H, Honma M, Tada Y, Mabuchi T, Higashiyama M, Kobayashi S, Hashimoto Y, Seishima M, Kakuma T.
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [Abstract] [Full Text] [Related]

  • 26. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M.
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.
    Lancet; 2017 Jul 15; 390(10091):276-288. PubMed ID: 28596043
    [Abstract] [Full Text] [Related]

  • 30. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
    Costanzo A, Llamas-Velasco M, Fabbrocini G, Cuccia A, Rivera-Diaz R, Gaarn Du Jardin K, Kasujee I, Puig L, Carrascosa JM.
    J Eur Acad Dermatol Venereol; 2023 Oct 15; 37(10):2004-2015. PubMed ID: 37246505
    [Abstract] [Full Text] [Related]

  • 31. Tildrakizumab for the treatment of psoriasis.
    Sinclair R, Thirthar Palanivelu V.
    Expert Rev Clin Immunol; 2019 Jan 15; 15(1):5-12. PubMed ID: 30394141
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2021 Apr 15; 35(4):928-937. PubMed ID: 33030755
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP, Bewley A, Hammond E, Hansen JB, Horne L, Paul C, Reich K, Seneschal J, De Simone C, Sohrt A, Augustin M, Pellacani G.
    Dermatol Ther (Heidelb); 2020 Oct 15; 10(5):1099-1109. PubMed ID: 32761560
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.